Alzinova
Alzinova: Another external validation (Redeye)
2021-01-15 08:30
Redeye comments on the news earlier this week that an Eli Lilly amyloid-beta (Aβ)-asset, donanemab, slowed cognitive decline in a phase 2 study. There are now several drug candidates targeting Aβ that has shown efficacy signals. It provides a validation of the Aβ hypothesis generally and for Alzinova's vaccine approach specifically.
info@redeye.se (Redeye.se)
Redeye AB - Redeye.se